source
stringlengths 2
222
| date
stringlengths 19
19
| url
stringlengths 22
853
⌀ | text
stringlengths 0
10k
⌀ | title
stringlengths 0
701
| context_id
stringlengths 1
9
| document_id
stringclasses 2
values | document_type
stringclasses 2
values |
|---|---|---|---|---|---|---|---|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-03-10 08:05:00
| null |
RODEHEAVER'S FINANCIAL ACUMEN ADDS TO THE COMPANY'S WORLD-CLASS TEAM RODEHEAVER'S FINANCIAL ACUMEN ADDS TO THE COMPANY'S WORLD-CLASS TEAM
|
XERIANT APPOINTS CHESTER RODEHEAVER TO ITS ADVISORY BOARD
|
XERI
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-03-08 08:05:00
| null |
ALLIANCE TO ACCELERATE DEVELOPMENT AND COMMERCIALIZATION OF NEXT-GEN AEROSPACE TECHNOLOGIES ALLIANCE TO ACCELERATE DEVELOPMENT AND COMMERCIALIZATION OF NEXT-GEN AEROSPACE TECHNOLOGIES
|
XERIANT FORMING STRATEGIC ALLIANCE WITH AWARD-WINNING AI COMPANY, THEINCLAB
|
XERI
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-03-03 08:05:00
| null |
THE COMPANY TAKES A KEY STEP TOWARDS ASSEMBLING A BROAD PORTFOLIO OF DISRUPTIVE TECHNOLOGIES IN AEROSPACE AND RELATED INDUSTRIES THE COMPANY TAKES A KEY STEP TOWARDS ASSEMBLING A BROAD PORTFOLIO OF DISRUPTIVE TECHNOLOGIES IN AEROSPACE AND RELATED INDUSTRIES
|
XERIANT PREPARING REGULATION A OFFERING TO ACCELERATE DEVELOPMENT OF NEXT-GEN AEROSPACE TECHNOLOGIES
|
XERI
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-02-03 08:05:00
| null |
NOTED IMPROVEMENT IN FUEL EFFICIENCY, PERFORMANCE AND ENGINE WEAR. XERIANT EXPECTS SIGNIFICANT REVENUE, SALES BEGINNING IN 2021
|
XERI NANO-LUBRICANTS DEMONSTRATE DRAMATIC ANTI-FRICTION EFFECT IN INITIAL AUTOMOBILE TESTING
|
XERI
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-01-28 08:05:00
| null |
BOCA RATON, FLA., JAN. 28, 2021 (GLOBE NEWSWIRE) -- XERIANT, INC. (OTC PINK: XERI), A NEW AEROSPACE TECHNOLOGY HOLDING COMPANY, ANNOUNCED TODAY THAT ITS STRATEGIC ALLIANCE PARTNER, XERIANT EUROPE S.R.O., HAS SIGNED A PURCHASE AGREEMENT FOR ITS XERI LUBRICANT PRODUCTS IN AUSTRALIA. THE SALES CONTRACT FOLLOWS THE SUCCESSFUL TESTING OF XERI 'S REVOLUTIONARY ANTI-FRICTION “GREEN” LUBRICANT ON AN AUSTRALIAN BRAND OF ELECTRICALLY-POWERED SCOOTERS.
|
XERI BRAND NANO-LUBRICANT GENERATES INITIAL SALES IN AUSTRALIA FOLLOWING SUCCESSFUL PRODUCT TEST
|
XERI
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-01-20 07:05:00
| null |
NEW SENIOR ADVISOR BRINGS OVER 30 YEARS OF EXPERIENCE IN SUSTAINABILITY AND ACCELERATING NEW TECHNOLOGIES NEW SENIOR ADVISOR BRINGS OVER 30 YEARS OF EXPERIENCE IN SUSTAINABILITY AND ACCELERATING NEW TECHNOLOGIES
|
XERIANT APPOINTS FORMER KEY BOEING ECO-AVIATION AND INNOVATION EXECUTIVE
|
XERI
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-01-13 08:05:00
| null |
BREAKTHROUGH GREEN ANTI-FRICTION TECHNOLOGY SEEKS TO DISRUPT $55 BILLION INDUSTRY BREAKTHROUGH GREEN ANTI-FRICTION TECHNOLOGY SEEKS TO DISRUPT $55 BILLION INDUSTRY
|
XERI NANOTECH LUBRICANTS PRODUCE INITIAL SALES
|
XERI
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2020-12-30 08:05:00
| null |
SIGNS LOI TO ACQUIRE INTEREST IN STRATEGIC ALLIANCE PARTNER
|
XERIANT PROJECTS SIGNIFICANT REVENUE THROUGH ACQUISITION OF EUROPEAN OPERATIONS
|
XERI
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-06-21 07:00:00
| null |
CHICAGO--(BUSINESS WIRE)-- #GVOKEHYPOPEN--XERIS BIOPHARMA HOLDINGS, INC. (NASDAQ: XERS), A GROWTH-ORIENTED BIOPHARMACEUTICAL COMPANY COMMITTED TO IMPROVING PATIENTS' LIVES BY DEVELOPING AND COMMERCIALIZING INNOVATIVE PRODUCTS ACROSS A RANGE OF THERAPIES, TODAY ANNOUNCED THAT THE FIRST PARTICIPANT HAS BEEN DOSED IN A MULTI-CENTER, OPEN LABEL, PHASE 2 STUDY OF XP-8121 FOR THE TREATMENT OF ADULTS WITH HYPOTHYROIDISM. “ORAL LEVOTHYROXINE IS ONE OF THE MOST PRESCRIBED MEDICINES IN THE UNITED STATES, GENERATING MORE.
|
XERIS BIOPHARMA ANNOUNCES FIRST PARTICIPANT DOSED IN A PHASE 2 CLINICAL STUDY OF ITS INVESTIGATIONAL SUBCUTANEOUS (SC) LEVOTHYROXINE (XP-8121) IN PATIENTS WITH HYPOTHYROIDISM
|
XERS
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-06-01 07:00:00
| null |
CHICAGO--(BUSINESS WIRE)-- #GVOKEHYPOPEN--XERIS BIOPHARMA HOLDINGS, INC. (NASDAQ: XERS), A GROWTH-ORIENTED BIOPHARMACEUTICAL COMPANY COMMITTED TO IMPROVING PATIENTS' LIVES BY DEVELOPING AND COMMERCIALIZING INNOVATIVE PRODUCTS ACROSS A RANGE OF THERAPIES, TODAY ANNOUNCED THAT MEMBERS OF ITS SENIOR MANAGEMENT WILL PARTICIPATE IN A FIRESIDE CHAT AT THE JEFFERIES HEALTHCARE CONFERENCE ON THURSDAY, JUNE 8 AT 10:30AM EASTERN TIME. A LIVE WEBCAST OF THE EVENT WILL BE AVAILABLE ON THE 'EVENTS & PRESENTATIONS' SECT.
|
XERIS BIOPHARMA TO PARTICIPATE AT THE JEFFERIES HEALTHCARE CONFERENCE
|
XERS
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-04-18 07:00:00
| null |
CHICAGO--(BUSINESS WIRE)-- #GVOKEHYPOPEN--XERIS BIOPHARMA HOLDINGS, INC. (NASDAQ: XERS), A GROWTH-ORIENTED BIOPHARMACEUTICAL COMPANY COMMITTED TO IMPROVING PATIENTS' LIVES BY DEVELOPING AND COMMERCIALIZING INNOVATIVE PRODUCTS ACROSS A RANGE OF THERAPIES, TODAY ANNOUNCED THAT THE U.S. PATENT AND TRADEMARK OFFICE HAS ISSUED US PATENT NUMBER 11,590,205, ENTITLED ‘METHODS FOR PRODUCING STABLE THERAPEUTIC GLUCAGON FORMULATIONS IN APROTIC POLAR SOLVENTS.
|
XERIS BIOPHARMA ANNOUNCES ISSUANCE OF U.S. PATENT COVERING XERISOL™ FORMULATIONS
|
XERS
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-03-30 07:00:00
| null |
CHICAGO--(BUSINESS WIRE)-- #GVOKEHYPOPEN--XERIS BIOPHARMA HOLDINGS, INC. (NASDAQ: XERS), A GROWTH-ORIENTED BIOPHARMACEUTICAL COMPANY COMMITTED TO IMPROVING PATIENT LIVES BY DEVELOPING AND COMMERCIALIZING INNOVATIVE PRODUCTS ACROSS A RANGE OF THERAPEUTIC AREAS, TODAY ANNOUNCED THAT IT HAS ENTERED INTO A PLATFORM RESEARCH EVALUATION COLLABORATION AND OPTION AGREEMENT WITH REGENERON PHARMACEUTICALS, INC.
|
XERIS BIOPHARMA ANNOUNCES RESEARCH EVALUATION COLLABORATION AND OPTION AGREEMENT WITH REGENERON FOR XERIJECT™
|
XERS
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-03-08 06:00:00
| null |
CHICAGO--(BUSINESS WIRE)-- #GVOKEHYPOPEN--XERIS BIOPHARMA HOLDINGS, INC. (NASDAQ: XERS), A GROWTH-ORIENTED BIOPHARMACEUTICAL COMPANY COMMITTED TO IMPROVING PATIENTS' LIVES BY DEVELOPING AND COMMERCIALIZING INNOVATIVE PRODUCTS ACROSS A RANGE OF THERAPIES, TODAY ANNOUNCED FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FULL-YEAR 2022 AND PROVIDED 2023 FINANCIAL GUIDANCE.
|
XERIS BIOPHARMA REPORTS FOURTH QUARTER AND FULL-YEAR 2022 FINANCIAL RESULTS AND PROVIDES 2023 FINANCIAL GUIDANCE
|
XERS
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-02-02 07:00:00
| null |
CHICAGO--( BUSINESS WIRE )--XERIS BIOPHARMA, INC. (NASDAQ: XERS), A GROWTH-ORIENTED BIOPHARMACEUTICAL COMPANY COMMITTED TO IMPROVING PATIENT LIVES BY DEVELOPING AND COMMERCIALIZING INNOVATIVE PRODUCTS ACROSS A RANGE OF THERAPIES, TODAY ANNOUNCED THAT MEMBERS OF ITS SENIOR MANAGEMENT WILL HOLD 1X1 INVESTOR MEETINGS AND PRESENT AN OVERVIEW OF THE COMPANY AT THE SVB SECURITIES GLOBAL BIOPHARMA CONFERENCE 2023, WHICH IS TAKING PLACE IN A VIRTUAL FORMAT.
|
XERIS BIOPHARMA TO PARTICIPATE IN THE SVB SECURITIES GLOBAL BIOPHARMA CONFERENCE 2023
|
XERS
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-01-30 07:00:00
| null |
CHICAGO--( BUSINESS WIRE )--XERIS BIOPHARMA HOLDINGS, INC. (NASDAQ: XERS), A GROWTH-ORIENTED BIOPHARMACEUTICAL COMPANY COMMITTED TO IMPROVING PATIENT LIVES BY DEVELOPING AND COMMERCIALIZING INNOVATIVE PRODUCTS ACROSS A RANGE OF THERAPIES, TODAY ANNOUNCED THAT THE FOOD AND DRUG ADMINISTRATION (FDA) GRANTED ITS SUBSIDIARY XERIS PHARMACEUTICALS, INC., ORPHAN-DRUG EXCLUSIVITY (ODE) FOR RECORLEV® (LEVOKETOCONAZOLE) FOR THE TREATMENT OF ADULT PATIENTS WITH ENDOGENOUS CUSHING'S SYNDROME FOR WHOM SURGERY IS NOT AN OPTION OR HAS NOT BEEN CURATIVE.
|
XERIS BIOPHARMA ANNOUNCES FDA GRANTS ORPHAN-DRUG EXCLUSIVITY FOR RECORLEV®
|
XERS
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-01-05 07:00:00
| null |
CHICAGO--( BUSINESS WIRE )--XERIS BIOPHARMA HOLDINGS, INC. (NASDAQ: XERS), A GROWTH-ORIENTED BIOPHARMACEUTICAL COMPANY COMMITTED TO IMPROVING PATIENTS' LIVES BY DEVELOPING AND COMMERCIALIZING INNOVATIVE PRODUCTS ACROSS A RANGE OF THERAPIES, TODAY ANNOUNCED THAT, IN CONNECTION WITH INVESTOR MEETINGS THE COMPANY IS PLANNING TO CONDUCT NEXT WEEK IN SAN FRANCISCO, IT HAS UPDATED ITS OUTLOOK FOR FULL YEAR 2022 EXPECTING NET PRODUCT REVENUE TO BE AT THE TOP OF ITS GUIDANCE RANGE OF $105 MILLION TO $110 MILLION AND ITS YEAR-END CASH BALANCE TO BE ABOVE THE PREVIOUSLY ANNOUNCED RANGE OF $110 MILLION TO $120 MILLION.
|
XERIS BIOPHARMA UPDATES ITS OUTLOOK FOR 2022
|
XERS
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-12-15 07:00:00
| null |
CHICAGO--( BUSINESS WIRE )--XERIS BIOPHARMA HOLDINGS, INC. (NASDAQ: XERS), A GROWTH-ORIENTED BIOPHARMACEUTICAL COMPANY COMMITTED TO IMPROVING PATIENT LIVES BY DEVELOPING AND COMMERCIALIZING INNOVATIVE PRODUCTS ACROSS A RANGE OF THERAPIES, TODAY ANNOUNCED THAT, BASED ON FEEDBACK FROM A TYPE C MEETING WITH THE FOOD AND DRUG ADMINISTRATION (FDA), XERIS WILL PROCEED WITH A PHASE II STUDY IN PATIENTS FOR ITS NOVEL FORMULATION OF LEVOTHYROXINE SODIUM (SC INJECTION) AS REPLACEMENT THERAPY FOR HYPOTHYROIDISM. THE COMPANY ANTICIPATES INITIATING THE STUDY BY THE SECOND HALF OF 2023.
|
XERIS BIOPHARMA ANNOUNCES PLANS FOR A PHASE II DOSE-FINDING STUDY FOR ITS INVESTIGATIONAL SUBCUTANEOUS (SC) LEVOTHYROXINE (XP-8121) AS REPLACEMENT THERAPY FOR HYPOTHYROIDISM
|
XERS
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-11-23 06:00:00
| null |
CHICAGO--( BUSINESS WIRE )--XERIS BIOPHARMA HOLDINGS, INC. (NASDAQ: XERS), A GROWTH-ORIENTED BIOPHARMACEUTICAL COMPANY COMMITTED TO IMPROVING PATIENT LIVES BY DEVELOPING AND COMMERCIALIZING INNOVATIVE PRODUCTS ACROSS A RANGE OF THERAPIES, TODAY ANNOUNCED THAT IT HAS ENTERED INTO A RESEARCH COLLABORATION AND OPTION AGREEMENT WITH HORIZON THERAPEUTICS PLC (NASDAQ: HZNP). UNDER THE TERMS OF THE AGREEMENT, XERIS WILL USE ITS PROPRIETARY FORMULATION TECHNOLOGY PLATFORM, XERIJECT™, TO DEVELOP AN ULTRA-CONCENTRATED, READY-TO-USE, SUBCUTANEOUS INJECTION OF TEPROTUMUMAB AND HORIZON WILL HAVE AN OPTION TO LICENSE THE XERIS TECHNOLOGY. TEPROTUMUMAB IS THE FIRST AND ONLY MEDICINE APPROVED BY THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) FOR THE TREATMENT OF THYROID EYE DISEASE (TED) – A SERIOUS, PROGRESSIVE AND POTENTIALLY VISION-THREATENING RARE AUTOIMMUNE DISEASE. TEPROTUMUMAB-TRBW IS KNOWN AS TEPEZZA® IN THE UNITED STATES. XERIS WILL RECEIVE AN UPFRONT PAYMENT, AND MAY BE ENTITLED TO RECEIVE DEVELOPMENT MILESTONES, REGULATORY MILESTONES, AND SALES-BASED MILESTONES, AS WELL AS ROYALTIES BASED ON FUTURE SALES IF THE COMMERCIAL LICENSE OPTION IS EXERCISED. SPECIFIC FINANCIAL TERMS OF THE AGREEMENT WERE NOT DISCLOSED.
|
XERIS BIOPHARMA ANNOUNCES RESEARCH COLLABORATION AND OPTION AGREEMENT WITH HORIZON THERAPEUTICS PLC FOR XERIJECT™ FORMULATION OF TEPROTUMUMAB
|
XERS
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-11-09 07:00:00
| null |
CHICAGO--(BUSINESS WIRE)-- #GVOKEHYPOPEN--XERIS BIOPHARMA HOLDINGS, INC. (NASDAQ: XERS), A GROWTH-ORIENTED BIOPHARMACEUTICAL COMPANY COMMITTED TO IMPROVING PATIENT LIVES BY DEVELOPING AND COMMERCIALIZING INNOVATIVE PRODUCTS ACROSS A RANGE OF THERAPIES, TODAY ANNOUNCED FINANCIAL RESULTS FOR THE THIRD QUARTER AND NINE MONTHS ENDED SEPTEMBER 30, 2022 AND OTHER CORPORATE HIGHLIGHTS.
|
XERIS BIOPHARMA REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS AND RECENT EVENTS
|
XERS
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-11-01 07:00:00
| null |
CHICAGO--(BUSINESS WIRE)-- #GVOKEHYPOPEN--XERIS BIOPHARMA HOLDINGS, INC. (NASDAQ: XERS), A GROWTH-ORIENTED BIOPHARMACEUTICAL COMPANY COMMITTED TO IMPROVING PATIENTS' LIVES BY DEVELOPING AND COMMERCIALIZING INNOVATIVE PRODUCTS ACROSS A RANGE OF THERAPIES, TODAY ANNOUNCED THAT THE EUROPEAN JOURNAL OF ENDOCRINOLOGY (EJE) PUBLISHED THE EXTENDED EVALUATION (EE) RESULTS OF THE SONICS STUDY (NCT01838551) EVALUATING LONGER-TERM EFFECTS OF LEVOKETOCONAZOLE ON CORTISOL LEVELS, BIOMARKERS OF CUSHING'S SYNDROME (CS) COMOR
|
XERIS BIOPHARMA ANNOUNCES RESULTS OF THE EXTENDED EVALUATION OF RECORLEV® (LEVOKETOCONAZOLE) FROM THE PHASE 3 SONICS STUDY PUBLISHED IN THE EUROPEAN JOURNAL OF ENDOCRINOLOGY
|
XERS
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-08-10 07:00:00
| null |
CHICAGO--(BUSINESS WIRE)--XERIS BIOPHARMA HOLDINGS, INC. (NASDAQ: XERS), A GROWTH-ORIENTED BIOPHARMACEUTICAL COMPANY COMMITTED TO IMPROVING PATIENT LIVES BY DEVELOPING AND COMMERCIALIZING INNOVATIVE PRODUCTS ACROSS A RANGE OF THERAPIES, TODAY ANNOUNCED FINANCIAL RESULTS FOR THE SECOND QUARTER AND SIX MONTHS ENDED JUNE 30, 2022 AND UPCOMING EVENTS. “WE CONTINUE TO EXECUTE OUR GROWTH STRATEGY AND ARE PLEASED TO HAVE POSTED RECORD NET REVENUE IN THE SECOND QUARTER. DEMAND FOR GVOKE HYPOPEN REMAINS
|
XERIS BIOPHARMA REPORTS SECOND QUARTER FINANCIAL RESULTS AND UPCOMING EVENTS
|
XERS
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-08-01 07:30:00
| null |
CHICAGO--(BUSINESS WIRE)-- #GVOKEHYPOPEN--XERIS BIOPHARMA HOLDINGS, INC. (NASDAQ: XERS), A BIOPHARMACEUTICAL COMPANY DEVELOPING AND COMMERCIALIZING UNIQUE THERAPIES FOR PATIENT POPULATIONS IN ENDOCRINOLOGY AND NEUROLOGY, TODAY ANNOUNCED THAT TETRIS PHARMA—ITS COMMERCIALIZATION PARTNER FOR OGLUO IN THE UK, EEA, AND SWITZERLAND—WILL BE ACQUIRED BY ARECOR THERAPEUTICS (AIM: AREC), A UK-BASED, PUBLICLY TRADED, GLOBALLY FOCUSED BIOPHARMACEUTICAL COMPANY, CONTINGENT UPON A SUCCESSFUL CAPITAL OFFERING BY ARECOR THERA
|
XERIS' COMMERCIALIZATION PARTNER FOR OGLUO®, TETRIS PHARMA LTD, TO BE ACQUIRED BY ARECOR THERAPEUTICS
|
XERS
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-03-10 07:00:00
| null |
CHICAGO--(BUSINESS WIRE)--XERIS BIOPHARMA HOLDINGS, INC. (NASDAQ: XERS), A BIOPHARMACEUTICAL COMPANY DEVELOPING AND COMMERCIALIZING UNIQUE THERAPIES FOR PATIENT POPULATIONS IN ENDOCRINOLOGY, NEUROLOGY, AND GASTROENTEROLOGY, AND XERIS PHARMACEUTICALS, INC., TODAY ANNOUNCED FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FULL-YEAR 2021 AND RECENT HIGHLIGHTS. “DURING 2021, WE MADE SIGNIFICANT PROGRESS TOWARD ACHIEVING CRITICAL MASS AND BECOMING A FULLY INTEGRATED PHARMACEUTICAL COMPANY WITH THE ACQUI
|
XERIS BIOPHARMA REPORTS FOURTH QUARTER AND FULL-YEAR 2021 FINANCIAL RESULTS AND RECENT EVENTS
|
XERS
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-01-31 07:00:00
| null |
CHICAGO--(BUSINESS WIRE)--XERIS BIOPHARMA HOLDINGS, INC. (NASDAQ: XERS), A BIOPHARMACEUTICAL COMPANY DEVELOPING AND COMMERCIALIZING UNIQUE THERAPIES FOR PATIENT POPULATIONS IN ENDOCRINOLOGY, NEUROLOGY, AND GASTROENTEROLOGY, TODAY ANNOUNCED THAT RECORLEV® (LEVOKETOCONAZOLE) IS NOW AVAILABLE FOR PRESCRIPTION. THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) APPROVED RECORLEV ON DECEMBER 31, 2021 FOR THE TREATMENT OF ENDOGENOUS HYPERCORTISOLEMIA IN ADULT PATIENTS WITH CUSHING'S SYNDROME FOR WHOM SURGER
|
XERIS BIOPHARMA ANNOUNCES RECORLEV® (LEVOKETOCONAZOLE) IS NOW COMMERCIALLY AVAILABLE FOR THE TREATMENT OF ENDOGENOUS HYPERCORTISOLEMIA IN ADULT PATIENTS WITH CUSHING'S SYNDROME
|
XERS
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-01-18 07:00:00
| null |
CHICAGO--(BUSINESS WIRE)--XERIS BIOPHARMA HOLDINGS, INC. (NASDAQ: XERS) (“XERIS” OR THE “COMPANY”), A BIOPHARMACEUTICAL COMPANY DEVELOPING AND COMMERCIALIZING UNIQUE THERAPIES FOR PATIENT POPULATIONS IN ENDOCRINOLOGY, NEUROLOGY, AND GASTROENTEROLOGY, TODAY ANNOUNCED A BUSINESS UPDATE AND REAFFIRMED ITS 2021 PRO FORMA NET SALES AND YEAR-END CASH BALANCE GUIDANCE. “WE ARE PROUD TO HAVE ENDED 2021 ON A STRONG NOTE WITH CONTINUED GROWTH OF GVOKE AND KEVEYIS®, DELIVERING NET SALES AT THE UPPER END O
|
XERIS BIOPHARMA REAFFIRMS 2021 GUIDANCE AND PROVIDES BUSINESS UPDATE
|
XERS
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-01-03 07:00:00
| null |
CHICAGO--(BUSINESS WIRE)--XERIS BIOPHARMA HOLDINGS, INC. (NASDAQ: XERS) (“XERIS” OR THE “COMPANY”), A BIOPHARMACEUTICAL COMPANY DEVELOPING AND COMMERCIALIZING UNIQUE THERAPIES FOR PATIENT POPULATIONS IN ENDOCRINOLOGY, NEUROLOGY, AND GASTROENTEROLOGY, TODAY ANNOUNCED THAT ON JANUARY 2, 2022, IT ENTERED INTO A SECURITIES PURCHASE AGREEMENT IN CONNECTION WITH A PRIVATE PLACEMENT (THE “PRIVATE PLACEMENT”) WITH AN AFFILIATE OF ARMISTICE CAPITAL, LLC (“ARMISTICE”) FOR AGGREGATE GROSS PROCEEDS OF APPR
|
XERIS BIOPHARMA ENTERS INTO AGREEMENT FOR $30 MILLION PRIVATE PLACEMENT
|
XERS
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-12-30 16:30:00
| null |
CHICAGO--(BUSINESS WIRE)--XERIS BIOPHARMA HOLDINGS, INC. (NASDAQ: XERS), A BIOPHARMACEUTICAL COMPANY DEVELOPING AND COMMERCIALIZING UNIQUE THERAPIES FOR PATIENT POPULATIONS IN ENDOCRINOLOGY, NEUROLOGY, AND GASTROENTEROLOGY, TODAY ANNOUNCED THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) APPROVAL OF RECORLEV® (LEVOKETOCONAZOLE) FOR THE TREATMENT OF ENDOGENOUS HYPERCORTISOLEMIA IN ADULT PATIENTS WITH CUSHING'S SYNDROME FOR WHOM SURGERY IS NOT AN OPTION OR HAS NOT BEEN CURATIVE.1 “WE ARE THRILLED WITH
|
XERIS BIOPHARMA ANNOUNCES U.S. FDA APPROVAL OF RECORLEV® (LEVOKETOCONAZOLE) FOR THE TREATMENT OF ENDOGENOUS HYPERCORTISOLEMIA IN ADULT PATIENTS WITH CUSHING'S SYNDROME
|
XERS
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-11-18 08:30:00
| null |
DURHAM, N.C., NOV. 18, 2021 (GLOBE NEWSWIRE) -- AERAMI THERAPEUTICS, INC. (THE “COMPANY”), A LEADER IN THE FIELD OF DEVELOPING INHALED THERAPIES TO TREAT SEVERE RESPIRATORY AND CHRONIC DISEASES, TODAY ANNOUNCED THE APPOINTMENT OF BARRY DEUTSCH AS CHIEF FINANCIAL OFFICER EFFECTIVE NOVEMBER 15, 2021.
|
AERAMI THERAPEUTICS APPOINTS BARRY DEUTSCH AS CHIEF FINANCIAL OFFICER
|
XERS
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-10-25 07:30:00
| null |
CHICAGO--(BUSINESS WIRE)--XERIS BIOPHARMA HOLDINGS, INC. (NASDAQ: XERS), A BIOPHARMACEUTICAL COMPANY DEVELOPING AND COMMERCIALIZING UNIQUE THERAPIES FOR PATIENT POPULATIONS IN ENDOCRINOLOGY, NEUROLOGY, AND GASTROENTEROLOGY, TODAY ANNOUNCED A COLLABORATION AGREEMENT WITH MERCK , WITH AN OPTION TO LICENSE XERIS' SUSPENSION-BASED FORMULATION TECHNOLOGY, XERIJECT™, FOR USE WITH UNDISCLOSED MONOCLONAL ANTIBODIES (MABS) FOR THE PURPOSE OF ENGINEERING ULTRA-HIGH CONCENTRATION, READY-TO-USE FORMULATION
|
XERIS PHARMACEUTICALS ENTERS COLLABORATION AGREEMENT WITH MERCK
|
XERS
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-10-01 16:05:00
| null |
CHICAGO--(BUSINESS WIRE)--XERIS PHARMACEUTICALS, INC. (NASDAQ: XERS), A PHARMACEUTICAL COMPANY LEVERAGING ITS NOVEL TECHNOLOGY PLATFORMS TO DEVELOP AND COMMERCIALIZE READY-TO-USE INJECTABLE AND INFUSIBLE DRUG FORMULATIONS, TODAY ANNOUNCED THAT ON OCTOBER 1, 2021, THE COMPENSATION COMMITTEE OF XERIS' BOARD OF DIRECTORS GRANTED RESTRICTED STOCK UNITS FOR AN AGGREGATE OF 28,750 SHARES OF ITS COMMON STOCK TO 20 NEW EMPLOYEE(S) UNDER XERIS' INDUCEMENT EQUITY PLAN. XERIS' INDUCEMENT EQUITY PLAN IS US
|
XERIS PHARMACEUTICALS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
|
XERS
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-09-14 16:05:00
| null |
CHICAGO--(BUSINESS WIRE)--XERIS PHARMACEUTICALS, INC. (NASDAQ: XERS) (“XERIS”) TODAY ANNOUNCED THAT ITS STOCKHOLDERS HAVE VOTED TO APPROVE THE PREVIOUSLY ANNOUNCED PROPOSED ACQUISITION OF STRONGBRIDGE BIOPHARMA PLC (NASDAQ: SBBP) (“STRONGBRIDGE”) BY XERIS. AT THE SPECIAL MEETING OF XERIS STOCKHOLDERS HELD ON SEPTEMBER 14, 2021, APPROXIMATELY 97% OF THE SHARES VOTED WERE CAST IN FAVOR OF THE ACQUISITION, REPRESENTING APPROXIMATELY 59% OF XERIS' TOTAL OUTSTANDING SHARES OF COMMON STOCK. XERIS WIL
|
XERIS PHARMACEUTICALS STOCKHOLDERS APPROVE ACQUISITION OF STRONGBRIDGE BIOPHARMA
|
XERS
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-09-01 07:30:00
| null |
CHICAGO--(BUSINESS WIRE)--XERIS PHARMACEUTICALS, INC. (NASDAQ: XERS), A SPECIALTY PHARMACEUTICAL COMPANY LEVERAGING ITS NOVEL FORMULATION TECHNOLOGY PLATFORMS TO DEVELOP AND COMMERCIALIZE READY-TO-USE INJECTABLE DRUG FORMULATIONS, TODAY ANNOUNCED THAT THE COMPANY HAS COMPLETED ENROLLMENT AND SUCCESSFULLY DOSED ALL PARTICIPANTS IN A PHASE 1 STUDY OF LEVOTHYROXINE (XP-8121) TO EVALUATE THE PHARMACOKINETICS, SAFETY AND TOLERABILITY, AND POTENTIAL FOR WEEKLY DOSING OF THE INVESTIGATIONAL, NOVEL, SU
|
XERIS PHARMACEUTICALS COMPLETES ENROLLMENT OF ITS PHASE 1 STUDY OF LEVOTHYROXINE (XP-8121)
|
XERS
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-08-19 08:00:00
| null |
CHICAGO--(BUSINESS WIRE)--XERIS PHARMACEUTICALS, INC. (NASDAQ: XERS), A PHARMACEUTICAL COMPANY LEVERAGING ITS NOVEL FORMULATION TECHNOLOGY PLATFORMS TO DEVELOP AND COMMERCIALIZE READY-TO-USE INJECTABLE AND INFUSIBLE DRUG FORMULATIONS, TODAY ANNOUNCED THAT IT HAS RECENTLY BEEN GRANTED THREE NEW PATENTS RELATING TO ITS FORMULATION TECHNOLOGY PLATFORMS. THE U.S. PATENT AND TRADEMARK OFFICE GRANTED U.S. PATENT NOS. 10,987,399 AND 11,020,403 TO XERIS, AND THE CHINA INTELLECTUAL PROPERTY OFFICE GRANT
|
XERIS PHARMACEUTICALS STRENGTHENS ITS PATENT ESTATE
|
XERS
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-08-13 08:00:00
| null |
CHICAGO--(BUSINESS WIRE)--XERIS PHARMACEUTICALS, INC. (NASDAQ: XERS), A PHARMACEUTICAL COMPANY LEVERAGING ITS NOVEL FORMULATION TECHNOLOGY PLATFORMS TO DEVELOP AND COMMERCIALIZE READY-TO-USE INJECTABLE AND INFUSIBLE DRUG FORMULATIONS, TODAY ANNOUNCED THE ACHIEVEMENT OF AN IMPORTANT MILESTONE OF PAYOR COVERAGE FOR GVOKE – A READY-TO-USE GLUCAGON FOR THE TREATMENT OF SEVERE HYPOGLYCEMIA FOR ADULTS AND CHILDREN WITH DIABETES AGES 2 AND ABOVE. TODAY, APPROXIMATELY 91% OF MEDICARE PATIENTS, 88% OF C
|
XERIS PHARMACEUTICALS ACHIEVES UNPRECEDENTED LEVELS OF PAYOR COVERAGE FOR GVOKE®
|
XERS
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-07-19 08:00:00
| null |
CHICAGO--(BUSINESS WIRE)--XERIS PHARMACEUTICALS, INC. (NASDAQ: XERS), A SPECIALTY PHARMACEUTICAL COMPANY LEVERAGING ITS NOVEL FORMULATION TECHNOLOGY PLATFORMS TO DEVELOP AND COMMERCIALIZE READY-TO-USE INJECTABLE DRUG FORMULATIONS, TODAY ANNOUNCED AN EXCLUSIVE AGREEMENT WITH TETRIS PHARMA LIMITED (“TETRIS”) FOR THE COMMERCIALIZATION OF OGLUO® IN THE EUROPEAN ECONOMIC AREA, UNITED KINGDOM, AND SWITZERLAND (THE “TERRITORY”) FOR THE TREATMENT OF SEVERE HYPOGLYCAEMIA IN ADULTS, ADOLESCENTS, AND CHIL
|
XERIS PHARMACEUTICALS ENTERS INTO AN EXCLUSIVE LICENSE AND SUPPLY AGREEMENT WITH TETRIS PHARMA LIMITED TO COMMERCIALIZE OGLUO® IN EUROPE
|
XERS
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-07-02 16:05:00
| null |
CHICAGO--(BUSINESS WIRE)--XERIS PHARMACEUTICALS, INC. (NASDAQ: XERS), A SPECIALTY PHARMACEUTICAL COMPANY LEVERAGING ITS NOVEL TECHNOLOGY PLATFORMS TO DEVELOP AND COMMERCIALIZE READY-TO-USE INJECTABLE DRUG FORMULATIONS, TODAY ANNOUNCED THAT ON JULY 1, 2021, THE COMPENSATION COMMITTEE OF XERIS' BOARD OF DIRECTORS GRANTED RESTRICTED STOCK UNITS FOR AN AGGREGATE OF 80,250 SHARES OF ITS COMMON STOCK TO 37 NEW EMPLOYEE(S) UNDER XERIS' INDUCEMENT EQUITY PLAN. XERIS' INDUCEMENT EQUITY PLAN IS USED EXCL
|
XERIS PHARMACEUTICALS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
|
XERS
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-05-28 16:38:00
| null |
NEW ORLEANS--(BUSINESS WIRE)--FORMER ATTORNEY GENERAL OF LOUISIANA CHARLES C. FOTI, JR., ESQ. AND THE LAW FIRM OF KAHN SWICK & FOTI, LLC (“KSF”) ARE INVESTIGATING THE PROPOSED SALE OF STRONGBRIDGE BIOPHARMA PLC (NASDAQGS: SBBP) TO XERIS PHARMACEUTICALS, INC. (NASDAQGS: XERS). UNDER THE TERMS OF THE PROPOSED TRANSACTION, SHAREHOLDERS OF STRONGBRIDGE WILL RECEIVE ONLY 0.7840 SHARES OF XERIS PLUS ONE CONTINGENT VALUE RIGHT FOR EACH SHARE OF STRONGBRIDGE THAT THEY OWN. KSF IS SEEKING TO DETERMI
|
STRONGBRIDGE BIOPHARMA INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: KAHN SWICK & FOTI, LLC INVESTIGATES ADEQUACY OF PRICE AND PROCESS IN PROPOSED SALE OF STRONGBRIDGE BIOPHARMA PLC - SBBP
|
XERS
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-05-24 18:30:00
| null |
NEW YORK--(BUSINESS WIRE)--HALPER SADEH LLP, A GLOBAL INVESTOR RIGHTS LAW FIRM, IS INVESTIGATING WHETHER THE MERGER OF XERIS PHARMACEUTICALS, INC. (NASDAQ: XERS) AND STRONGBRIDGE BIOPHARMA PLC IS FAIR TO XERIS SHAREHOLDERS. UPON CLOSING, XERIS SHAREHOLDERS WILL EXCHANGE EACH SHARE OF XERIX COMMON STOCK THEY OWN FOR 1 SHARE OF THE COMBINED COMPANY. CURRENT XERIS SHAREHOLDERS ARE EXPECTED TO OWN APPROXIMATELY 60% OF THE COMBINED COMPANY. HALPER SADEH ENCOURAGES XERIS SHAREHOLDERS TO CLICK HERE TO
|
XERIS MERGER INVESTIGATION: HALPER SADEH LLP ANNOUNCES INVESTIGATION INTO WHETHER THE MERGER OF XERIS PHARMACEUTICALS, INC. IS FAIR TO SHAREHOLDERS; INVESTORS ARE ENCOURAGED TO CONTACT THE FIRM – XERS
|
XERS
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-05-24 17:45:00
| null |
NEW YORK, MAY 24, 2021 /PRNEWSWIRE/ -- WEISSLAW LLP IS INVESTIGATING POSSIBLE BREACHES OF FIDUCIARY DUTY AND OTHER VIOLATIONS OF LAW BY THE BOARD OF DIRECTORS OF STRONGBRIDGE BIOPHARMA PLC ("STRONGBRIDGE" OR THE "COMPANY") (NASDAQ: SBBP) IN CONNECTION WITH THE COMPANY'S PROPOSED MERGER WITH XERIS PHARMACEUTICALS, INC. ("XERIS") (NASDAQ: XERS). UNDER THE TERMS OF THE MERGER AGREEMENT, STRONGBRIDGE SHAREHOLDERS WILL RECEIVE 0.7840 SHARES OF XERIS COMMON STOCK FOR EACH SHARE OF STRONGBRIDGE COMMON STOCK THAT THEY OWN, REPRESENTING IMPLIED PER-SHARE MERGER CONSIDERATION OF APPROXIMATELY $2.72 BASED UPON XERIS' MAY 21, 2021 CLOSING PRICE OF $3.47.
|
SHAREHOLDER ALERT: WEISSLAW LLP INVESTIGATES STRONGBRIDGE BIOPHARMA PLC
|
XERS
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-05-24 16:58:00
| null |
CHICAGO AND DUBLIN AND TREVOSE, PA., MAY 24, 2021 /PRNEWSWIRE/ -- XERIS PHARMACEUTICALS, INC. (NASDAQ: XERS), A PHARMACEUTICAL COMPANY LEVERAGING ITS NOVEL FORMULATION TECHNOLOGY PLATFORMS TO DEVELOP AND COMMERCIALIZE READY-TO-USE INJECTABLE DRUG FORMULATIONS, AND STRONGBRIDGE BIOPHARMA PLC (NASDAQ: SBBP), A GLOBAL COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT AND COMMERCIALIZATION OF THERAPIES FOR RARE DISEASES WITH SIGNIFICANT UNMET NEEDS, TODAY ANNOUNCED THAT THEY HAVE ENTERED INTO A DEFINITIVE AGREEMENT UNDER WHICH XERIS WILL ACQUIRE STRONGBRIDGE FOR STOCK AND CONTINGENT VALUE RIGHTS ("CVRS").
|
RULE 2.5 ANNOUNCEMENT: XERIS PHARMACEUTICALS, INC. TO ACQUIRE STRONGBRIDGE BIOPHARMA PLC IN STOCK AND CVR TRANSACTION, CREATING AN INNOVATIVE LEADER IN ENDOCRINOLOGY AND RARE DISEASES
|
XERS
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-05-24 07:00:00
| null |
CHICAGO & DUBLIN & TREVOSE, PA.--(BUSINESS WIRE)--XERIS PHARMACEUTICALS, INC. (“XERIS”) (NASDAQ: XERS), A PHARMACEUTICAL COMPANY LEVERAGING ITS NOVEL FORMULATION TECHNOLOGY PLATFORMS TO DEVELOP AND COMMERCIALIZE READY-TO-USE INJECTABLE DRUG FORMULATIONS, AND STRONGBRIDGE BIOPHARMA PLC (“STRONGBRIDGE”) (NASDAQ: SBBP), A GLOBAL COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT AND COMMERCIALIZATION OF THERAPIES FOR RARE DISEASES WITH SIGNIFICANT UNMET NEEDS, TODAY ANNOUNCED TH
|
XERIS PHARMACEUTICALS, INC. TO ACQUIRE STRONGBRIDGE BIOPHARMA PLC IN STOCK AND CVR TRANSACTION, CREATING AN INNOVATIVE LEADER IN ENDOCRINOLOGY AND RARE DISEASES
|
XERS
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-05-24 06:55:00
| null |
CHICAGO & DUBLIN & TREVOSE, PA.--(BUSINESS WIRE)--XERIS PHARMACEUTICALS, INC. (NASDAQ: XERS), A PHARMACEUTICAL COMPANY LEVERAGING ITS NOVEL FORMULATION TECHNOLOGY PLATFORMS TO DEVELOP AND COMMERCIALIZE READY-TO-USE INJECTABLE DRUG FORMULATIONS, AND STRONGBRIDGE BIOPHARMA PLC (NASDAQ: SBBP), A GLOBAL COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT AND COMMERCIALIZATION OF THERAPIES FOR RARE DISEASES WITH SIGNIFICANT UNMET NEEDS, TODAY ANNOUNCED THAT THEY HAVE ENTERED INTO A
|
RULE 2.5 ANNOUNCEMENT: XERIS PHARMACEUTICALS, INC. TO ACQUIRE STRONGBRIDGE BIOPHARMA PLC IN STOCK AND CVR TRANSACTION, CREATING AN INNOVATIVE LEADER IN ENDOCRINOLOGY AND RARE DISEASES
|
XERS
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-05-13 07:00:00
| null |
CHICAGO--(BUSINESS WIRE)--XERIS PHARMACEUTICALS, INC. (NASDAQ: XERS), A SPECIALTY PHARMACEUTICAL COMPANY LEVERAGING ITS NOVEL FORMULATION TECHNOLOGY PLATFORMS TO DEVELOP AND COMMERCIALIZE READY-TO-USE INJECTABLE DRUG FORMULATIONS, TODAY ANNOUNCED FINANCIAL RESULTS FOR THE FIRST QUARTER 2021 AND RECENT HIGHLIGHTS. “WE ARE VERY PLEASED WITH OUR STEADY, CONSISTENTLY GROWING FINANCIAL PERFORMANCE IN THE FIRST QUARTER NOTWITHSTANDING THE CONTINUED CHALLENGES CREATED BY THE GLOBAL PANDEMIC. DEMAND FO
|
XERIS PHARMACEUTICALS REPORTS FIRST QUARTER 2021 FINANCIAL RESULTS AND RECENT HIGHLIGHTS
|
XERS
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-03-14 20:22:00
| null |
NEW YORK, NEW YORK--(NEWSFILE CORP. - MARCH 14, 2021) - POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF XERIS PHARMACEUTICALS, INC. ("XERIS" OR THE "COMPANY") (NASDAQ: XERS). SUCH INVESTORS ARE ADVISED TO CONTACT ROBERT S. WILLOUGHBY AT NEWACTION@POMLAW.COM OR 888-476-6529, EXT. 7980.THE INVESTIGATION CONCERNS WHETHER XERIS AND CERTAIN OF ITS OFFICERS AND/OR DIRECTORS HAVE ENGAGED IN SECURITIES FRAUD OR OTHER UNLAWFUL BUSINESS PRACTICES. [CLICK HERE FOR INFORMATION ABOUT JOINING THE...
|
SHAREHOLDER ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF XERIS PHARMACEUTICALS, INC. - XERS
|
XERS
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-03-12 05:35:00
| null |
NEW YORK, MARCH 12, 2021 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF XERIS PHARMACEUTICALS, INC. ("XERIS" OR THE "COMPANY") (NASDAQ: XERS). SUCH INVESTORS ARE ADVISED TO CONTACT ROBERT S.
|
SHAREHOLDER ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF XERIS PHARMACEUTICALS, INC. - XERS
|
XERS
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-03-10 02:35:00
| null |
NEW YORK, MARCH 10, 2021 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF XERIS PHARMACEUTICALS, INC. ("XERIS" OR THE "COMPANY") (NASDAQ: XERS). SUCH INVESTORS ARE ADVISED TO CONTACT ROBERT S.
|
SHAREHOLDER ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF XERIS PHARMACEUTICALS, INC. - XERS
|
XERS
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-03-09 07:00:00
| null |
CHICAGO--(BUSINESS WIRE)-- #T1D--XERIS PHARMACEUTICALS, INC. (NASDAQ: XERS), A SPECIALTY PHARMACEUTICAL COMPANY LEVERAGING ITS NOVEL FORMULATION TECHNOLOGY PLATFORMS TO DEVELOP AND COMMERCIALIZE READY-TO-USE INJECTABLE AND INFUSIBLE DRUG FORMULATIONS, TODAY ANNOUNCED FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FULL-YEAR 2020 AND RECENT HIGHLIGHTS. “DESPITE THE OBVIOUS CHALLENGES OF 2020, I BELIEVE IT WAS A VERY SUCCESSFUL YEAR FOR XERIS, AND IN PARTICULAR, THE FOURTH QUARTER. WE SAW CONTINUOUS GROWTH
|
XERIS PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL-YEAR 2020 FINANCIAL RESULTS AND RECENT HIGHLIGHTS
|
XERS
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-02-26 16:05:00
| null |
CHICAGO--(BUSINESS WIRE)--XERIS PHARMACEUTICALS, INC. (NASDAQ: XERS), A SPECIALTY PHARMACEUTICAL COMPANY LEVERAGING ITS NOVEL TECHNOLOGY PLATFORMS TO DEVELOP AND COMMERCIALIZE READY-TO-USE INJECTABLE AND INFUSIBLE DRUG FORMULATIONS, TODAY ANNOUNCED THAT ON FEBRUARY 24, 2021, THE COMPENSATION COMMITTEE OF XERIS' BOARD OF DIRECTORS GRANTED NON-QUALIFIED STOCK OPTIONS FOR AN AGGREGATE OF 5,000 SHARES, AND RESTRICTED STOCK UNITS FOR AN AGGREGATE OF 9,500 SHARES, OF ITS COMMON STOCK TO 3 NEW EMPLOYE
|
XERIS PHARMACEUTICALS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
|
XERS
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-02-12 03:00:00
| null |
CHICAGO & DUBLIN--(BUSINESS WIRE)-- #GVOKEHYPOPEN--XERIS PHARMACEUTICALS, INC. (NASDAQ: XERS), A SPECIALTY PHARMACEUTICAL COMPANY LEVERAGING ITS NOVEL FORMULATION TECHNOLOGY PLATFORMS TO DEVELOP AND COMMERCIALIZE READY-TO-USE INJECTABLE AND INFUSIBLE DRUG FORMULATIONS, TODAY ANNOUNCED THAT THE EUROPEAN COMMISSION (EC) HAS APPROVED OGLUO™ (GLUCAGON) INJECTION FOR THE TREATMENT OF SEVERE HYPOGLYCAEMIA IN ADULTS, ADOLESCENTS, AND CHILDREN AGED 2 YEARS AND OVER WITH DIABETES MELLITUS. THE MARKETING AUTHORISATION I
|
XERIS PHARMACEUTICALS RECEIVES EUROPEAN COMMISSION APPROVAL OF OGLUO™ (GLUCAGON) INJECTION FOR THE TREATMENT OF SEVERE HYPOGLYCAEMIA IN ADULTS, ADOLESCENTS, AND CHILDREN AGED 2 YEARS AND OVER WITH DIABETES MELLITUS
|
XERS
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-01-29 16:05:00
| null |
CHICAGO--(BUSINESS WIRE)--XERIS PHARMACEUTICALS, INC. (NASDAQ: XERS), A SPECIALTY PHARMACEUTICAL COMPANY LEVERAGING ITS NOVEL TECHNOLOGY PLATFORMS TO DEVELOP AND COMMERCIALIZE READY-TO-USE INJECTABLE AND INFUSIBLE DRUG FORMULATIONS, TODAY ANNOUNCED THAT ON JANUARY 27, 2021, THE COMPENSATION COMMITTEE OF XERIS' BOARD OF DIRECTORS GRANTED NON-QUALIFIED STOCK OPTIONS FOR AN AGGREGATE OF 16,000 SHARES OF ITS COMMON STOCK TO 38 NEW EMPLOYEE(S) UNDER XERIS' INDUCEMENT EQUITY PLAN. XERIS' INDUCEMENT E
|
XERIS PHARMACEUTICALS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
|
XERS
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2020-12-31 16:05:00
| null |
CHICAGO--(BUSINESS WIRE)--XERIS PHARMACEUTICALS, INC. (NASDAQ: XERS), A SPECIALTY PHARMACEUTICAL COMPANY LEVERAGING ITS NOVEL TECHNOLOGY PLATFORMS TO DEVELOP AND COMMERCIALIZE READY-TO-USE INJECTABLE AND INFUSIBLE DRUG FORMULATIONS, TODAY ANNOUNCED THAT ON DECEMBER 30, 2020, THE COMPENSATION COMMITTEE OF XERIS' BOARD OF DIRECTORS GRANTED NON-QUALIFIED STOCK OPTIONS FOR AN AGGREGATE OF 38,250 SHARES, AND RESTRICTED STOCK UNITS FOR AN AGGREGATE OF 35,100 SHARES, OF ITS COMMON STOCK TO 7 NEW EMPLO
|
XERIS PHARMACEUTICALS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
|
XERS
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2020-12-22 07:00:00
| null |
CHICAGO--(BUSINESS WIRE)-- #GVOKEHYPOPEN--XERIS PHARMACEUTICALS, INC. (NASDAQ: XERS), A SPECIALTY PHARMACEUTICAL COMPANY LEVERAGING ITS NOVEL FORMULATION TECHNOLOGY PLATFORMS TO DEVELOP AND COMMERCIALIZE READY-TO-USE INJECTABLE AND INFUSIBLE DRUG FORMULATIONS, TODAY ANNOUNCED THAT IT HAS ENTERED INTO AN EXCLUSIVE DISTRIBUTION AGREEMENT WITH MEGAPHARM LTD. (“MEGAPHARM”), A LEADING ISRAEL-BASED PHARMACEUTICAL COMPANY, FOR THE COMMERCIALIZATION IN ISRAEL AND THE PALESTINIAN AUTHORITY OF XERIS' GVOKE® (GLUCAGON IN
|
XERIS PHARMACEUTICALS ANNOUNCES DISTRIBUTION AGREEMENT WITH MEGAPHARM LTD. TO COMMERCIALIZE GVOKE® IN ISRAEL AND THE PALESTINIAN AUTHORITY
|
XERS
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2020-12-11 04:00:00
| null |
CHICAGO--(BUSINESS WIRE)-- #GVOKEHYPOPEN--XERIS PHARMACEUTICALS, INC. (NASDAQ: XERS), A SPECIALTY PHARMACEUTICAL COMPANY LEVERAGING ITS NOVEL FORMULATION TECHNOLOGY PLATFORMS TO DEVELOP AND COMMERCIALIZE READY-TO-USE (RTU) INJECTABLE AND INFUSIBLE DRUG FORMULATIONS, ANNOUNCED THAT YESTERDAY THE EUROPEAN MEDICINES AGENCY'S COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) HAS ADOPTED A POSITIVE OPINION FOR OGLUO™ (GLUCAGON). OGLUO IS THE EU TRADE NAME FOR XERIS' RTU GLUCAGON FOR INJECTION. THE CHMP RECOMMEN
|
XERIS PHARMACEUTICALS RECEIVES POSITIVE CHMP OPINION FOR OGLUO™, ITS READY-TO-USE (RTU) GLUCAGON FOR INJECTION, FOR THE TREATMENT OF SEVERE HYPOGLYCAEMIA IN ADULTS, ADOLESCENTS, AND CHILDREN AGED 2 YEARS AND OVER WITH DIABETES MELLITUS
|
XERS
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2020-11-27 13:05:00
| null |
CHICAGO--(BUSINESS WIRE)--XERIS PHARMACEUTICALS, INC. (NASDAQ: XERS), A SPECIALTY PHARMACEUTICAL COMPANY LEVERAGING ITS NOVEL TECHNOLOGY PLATFORMS TO DEVELOP AND COMMERCIALIZE READY-TO-USE INJECTABLE AND INFUSIBLE DRUG FORMULATIONS, TODAY ANNOUNCED THAT ON NOVEMBER 25, 2020, THE COMPENSATION COMMITTEE OF XERIS' BOARD OF DIRECTORS GRANTED NON-QUALIFIED STOCK OPTIONS FOR AN AGGREGATE OF 18,000 SHARES, AND RESTRICTED STOCK UNITS FOR AN AGGREGATE OF 70,200 SHARES, OF ITS COMMON STOCK TO 11 NEW EMPL
|
XERIS PHARMACEUTICALS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
|
XERS
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2020-11-09 07:00:00
| null |
CHICAGO--(BUSINESS WIRE)-- #GVOKEHYPOPEN--XERIS PHARMACEUTICALS, INC. (NASDAQ: XERS), A SPECIALTY PHARMACEUTICAL COMPANY LEVERAGING ITS NOVEL FORMULATION TECHNOLOGY PLATFORMS TO DEVELOP AND COMMERCIALIZE READY-TO-USE (RTU) INJECTABLE AND INFUSIBLE DRUG FORMULATIONS, TODAY ANNOUNCED FINANCIAL RESULTS FOR THE THIRD QUARTER AND NINE MONTHS ENDED SEPTEMBER 30, 2020, AS WELL AS PIPELINE AND CORPORATE HIGHLIGHTS. “THE THIRD QUARTER RESULTS SHOWED THE TREMENDOUS RESPONSE FROM THE DIABETES COMMUNITY TO THE HIGHLY ANTI
|
XERIS PHARMACEUTICALS REPORTS THIRD QUARTER 2020 FINANCIAL RESULTS AND CORPORATE HIGHLIGHTS
|
XERS
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2020-10-30 16:05:00
| null |
CHICAGO--(BUSINESS WIRE)--XERIS PHARMACEUTICALS, INC. (NASDAQ: XERS), A SPECIALTY PHARMACEUTICAL COMPANY LEVERAGING ITS NOVEL TECHNOLOGY PLATFORMS TO DEVELOP AND COMMERCIALIZE READY-TO-USE INJECTABLE AND INFUSIBLE DRUG FORMULATIONS, TODAY ANNOUNCED THAT ON OCTOBER 28, 2020, THE COMPENSATION COMMITTEE OF XERIS' BOARD OF DIRECTORS GRANTED NON-QUALIFIED STOCK OPTIONS FOR AN AGGREGATE OF 36,250 SHARE(S) OF ITS COMMON STOCK TO 15 NEW EMPLOYEE(S) UNDER XERIS' INDUCEMENT EQUITY PLAN. XERIS' INDUCEMENT
|
XERIS PHARMACEUTICALS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
|
XERS
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2020-08-10 09:30:00
| null |
XERIS PHARMACEUTICALS REPORTS SECOND QUARTER 2020 FINANCIAL RESULTS AND CORPORATE HIGHLIGHTS.Q2 LOSS PER SHARE $0.63.Q2 SALES $2.0 MILLION VERSUS REFINITIV IBES ESTIMATE OF $1.9 MILLION.Q2 EARNINGS PER SHARE ESTIMATE $-0.73 -- REFINITIV IBES DATA.
|
XERIS PHARMACEUTICALS REPORTS Q2 LOSS PER SHARE $0.63
|
XERS
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2020-07-10 18:30:00
| null |
GEORGE SOROS REPORTS 5.6% PASSIVE STAKE IN XERIS PHARMACEUTICALS INC AS OF JUNE 30 - SEC FILING.
|
GEORGE SOROS REPORTS 5.6% PASSIVE STAKE IN XERIS PHARMACEUTICALS INC AS OF JUNE 30
|
XERS
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2020-06-15 08:30:00
| null |
XERIS PHARMACEUTICALS ANNOUNCES POSITIVE RESULTS FROM THE OUTPATIENT STAGE OF A PHASE 2 STUDY OF ITS DEVELOPMENTAL GVOKE READY-TO-USE (RTU) MICRO™ GLUCAGON IN ADULTS AT RISK OF HYPOGLYCEMIA DURING AND AFTER AEROBIC EXERCISE.XERIS PHARMACEUTICALS INC - STUDY ACHIEVED ALL PRIMARY OBJECTIVES.XERIS PHARMACEUTICALS INC - A MICRO DOSE OF GVOKE RTU MICRO DEMONSTRATED SAFETY AND TOLERABILITY PROFILE.
|
XERIS ANNOUNCES RESULTS FROM OUTPATIENT STAGE OF PHASE 2 STUDY OF DEVELOPMENTAL GVOKE READY-TO-USE MICRO GLUCAGON
|
XERS
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2020-05-22 10:30:00
| null |
XERIS PHARMACEUTICALS ANNOUNCES POSITIVE FINDINGS FROM THE OUTPATIENT PORTION OF A PHASE 2 PROOF-OF-CONCEPT STUDY OF ITS DEVELOPMENTAL READY-TO-USE (RTU) GLUCAGON IN PATIENTS AT RISK OF POSTPRANDIAL HYPOGLYCEMIA FOLLOWING BARIATRIC SURGERY.XERIS PHARMACEUTICALS - REBOUND HYPOGLYCEMIA OBSERVED IN PLACEBO ARM WITH ORAL GLUCOSE TABLET USE.XERIS PHARMACEUTICALS INC - NO REBOUND HYPOGLYCEMIA OBSERVED IN RTU GLUCAGON TREATMENT ARM.
|
XERIS PHARMACEUTICALS ANNOUNCES POSITIVE FINDINGS MID-STAGE STUDY OF ITS DEVELOPMENTAL GLUCAGON
|
XERS
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2020-05-07 11:30:00
| null |
XERIS PHARMACEUTICALS REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATES.Q1 LOSS PER SHARE $0.89.Q1 EARNINGS PER SHARE ESTIMATE $-0.89 -- REFINITIV IBES DATA.XERIS PHARMACEUTICALS - AS OF MARCH 31, 2020, REPORTED TOTAL CASH, CASH EQUIVALENTS, INVESTMENTS OF $99.9 MILLION, COMPARED TO $88.8 MILLION AT DEC 31, 2019.
|
XERIS PHARMACEUTICALS REPORTS Q1 2020 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATES
|
XERS
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2020-03-11 08:30:00
| null |
XERIS PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS AND HIGHLIGHTS PIPELINE PROGRESS.Q4 LOSS PER SHARE $1.23.Q4 EARNINGS PER SHARE ESTIMATE $-1.13 -- REFINITIV IBES DATA.XERIS PHARMACEUTICALS - CO IS ON TRACK FOR ITS PLANNED LAUNCH OF GVOKE HYPOPEN, ITS LIQUID STABLE GLUCAGON IN AN AUTO-INJECTOR, IN JULY 2020.XERIS PHARMACEUTICALS -AS OF DEC 31, 2019, XERIS REPORTED TOTAL CASH, CASH EQUIVALENTS, AND INVESTMENTS OF $88.8 MILLION.
|
XERIS PHARMACEUTICALS REPORTS Q4 LOSS PER SHARE OF $1.23
|
XERS
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2020-02-10 20:30:00
| null |
XERIS PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF 6,000,000 SHARES OF COMMON STOCK.
|
XERIS PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF 6,000,000 SHARES OF COMMON STOCK
|
XERS
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2019-12-10 21:30:00
| null |
XERIS PHARMACEUTICALS ANNOUNCES POSITIVE TOPLINE RESULTS FROM THE IN-CLINIC STAGE OF THE PHASE 2 STUDY OF ITS DEVELOPMENTAL READY-TO-USE (RTU) GLUCAGON IN PATIENTS AT RISK OF POSTPRANDIAL HYPOGLYCEMIA FOLLOWING BARIATRIC SURGERY.XERIS PHARMACEUTICALS - SUBCUTANEOUS RTU GLUCAGON IS SAFE AND WELL-TOLERATED.XERIS PHARMACEUTICALS INC - MINI DOSES OF RTU GLUCAGON APPEAR SAFE AND WELL TOLERATED.XERIS PHARMACEUTICALS - NO SERIOUS ADVERSE EVENTS OCCURRED.XERIS PHARMACEUTICALS - ADDITIONAL DATA WILL BE AVAILABLE IN FIRST HALF OF 2020.
|
XERIS PHARMACEUTICALS ANNOUNCES POSITIVE DATA FROM LOW BLOOD SUGAR TREATMENT TRIAL
|
XERS
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2019-11-20 22:30:00
| null |
XERIS PHARMACEUTICALS, INC. PRESENTS AT JEFFERIES 2019 LONDON HEALTHCARE CONFERENCE, NOV-21-2019 08:00 AM. VENUE: THE WALDORF HILTON HOTEL, ALDWYCH, LONDON, UNITED KINGDOM.
|
XERIS PHARMACEUTICALS, INC. PRESENTS AT JEFFERIES 2019 LONDON HEALTHCARE CONFERENCE, NOV-21-2019 08:00 AM
|
XERS
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2019-11-07 14:30:00
| null |
XERIS PHARMACEUTICALS REPORTS THIRD QUARTER 2019 FINANCIAL RESULTS AND HIGHLIGHTS.Q3 LOSS PER SHARE $1.22.Q3 EARNINGS PER SHARE ESTIMATE $-1.23 -- REFINITIV IBES DATA.
|
XERIS PHARMACEUTICALS Q3 LOSS PER SHARE $1.22
|
XERS
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2019-11-06 22:30:00
| null |
XERIS PHARMACEUTICALS, INC. ANNOUNCED EARNINGS RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2019. FOR THE THIRD QUARTER, THE COMPANY ANNOUNCED OPERATING LOSS WAS USD 30.082 MILLION COMPARED TO USD 14.943 MILLION A YEAR AGO. NET LOSS WAS USD 32.836 MILLION COMPARED TO USD 14.767 MILLION A YEAR AGO. BASIC LOSS PER SHARE WAS USD 1.22 COMPARED TO USD 0.71 A YEAR AGO. FOR THE NINE MONTHS, OPERATING LOSS WAS USD 89.579 MILLION COMPARED TO USD 39.030 MILLION A YEAR AGO. NET LOSS WAS USD 92.498 MILLION COMPARED TO USD 39.661 MILLION A YEAR AGO. BASIC LOSS PER SHARE WAS USD 3.58 COMPARED TO USD 4.36 A YEAR AGO.
|
XERIS PHARMACEUTICALS, INC. REPORTS EARNINGS RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2019
|
XERS
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2019-09-30 22:30:00
| null |
XERIS PHARMACEUTICALS, INC. APPOINTED MARK THIERER TO ITS BOARD OF DIRECTORS, INCREASING THE SIZE OF THE BOARD TO SEVEN MEMBERS, EFFECTIVE IMMEDIATELY. MR. THIERER WILL ALSO BE A MEMBER OF THE AUDIT COMMITTEE. MR. THIERER HAS A DEMONSTRATED TRACK RECORD OF SUCCESSFUL FINANCIAL AND OPERATIONAL STRATEGY THROUGH MORE THAN 30 YEARS OF EXPERIENCE IN THE HEALTHCARE INDUSTRY. HE CURRENTLY SERVES AS MANAGING PARTNER OF THE ASSETBLUE INVESTMENT GROUP, MOVING FROM HIS ROLE AS INTERIM CHIEF EXECUTIVE OFFICER OF DENTSPLY SIRONA. MR. THIERER PREVIOUSLY SERVED AS CHAIRMAN OF THE BOARD AND CEO OF CATAMARAN, HE BECAME CEO OF OPTUMRX, OVERSEEING ALL OPTUM PHARMACY CARE SERVICES. EARLIER IN HIS CAREER, MR. THIERER SUCCESSFULLY EXECUTED ROLES INCLUDING PRESIDENT, CEO AND CHAIRMAN OF SXC HEALTH SOLUTIONS, PRESIDENT OF PHYSICIANS INTERACTIVE.
|
XERIS PHARMACEUTICALS APPOINTS MARK THIERER TO BOARD OF DIRECTORS
|
XERS
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-06-15 08:30:00
| null |
MINNEAPOLIS, JUNE 15, 2023 (GLOBE NEWSWIRE) -- VIA IBN -- ELECTRONIC SERVITOR PUBLICATION NETWORK INC. (OTCQB: XESP) ANNOUNCES A NEW CHANNEL PARTNER WITH THE ADDITION OF IBN (INVESTOR BRAND NETWORK), A MULTIFACETED FINANCIAL NEWS AND PUBLISHING COMPANY FOR PRIVATE AND PUBLIC ENTITIES.
|
ELECTRONIC SERVITOR PUBLICATION NETWORK INC. ANNOUNCES IBN AS A STRATEGIC PARTNER IN ITS EXPANDING CHANNEL PARTNER STRATEGY
|
XESP
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2020-08-27 14:30:00
| null |
Q2 NET LOSS -5.9 MILLION USD.Q2 REVENUE 118.8 MILLION USD.Q3 2020 REVENUE IS EXPECTED IN RANGE OF USD 91-97 MILLION WITH AN EBITDA MARGIN IN RANGE OF 0-4%..GUIDANCE FOR Q3 2020 IS BASED ON AN AVERAGE EXCHANGE RATE OF 1.18 USD/EURO..Q2 BOOKINGS WERE USD 99.5 MILLION, DOWN 23% YOY AND 33% QOQ.Q2 NET LOSS WAS USD -5.9 MILLION, UP USD 2.2 MILLION YOY AND UP USD 0.8 MILLION QOQ.Q2 EBIT WAS USD -2.8 MILLION, UP USD 2.8 MILLION YOY AND DOWN USD 1.3 MILLION QOQ.Q2 REVENUE WAS USD 118.8 MILLION.CAPITAL EXPENDITURES IN Q2 WERE REDUCED SUBSTANTIALLY TO USD 7.5 MILLION, DOWN 64% COMPARED TO SAME QUARTER LAST YEAR.
|
X FAB SILICON FOUNDRIES Q2 EBIT LOSS NARROWS TO 2.8 MILLION DOLLARS
|
XFAB.PA
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2020-07-13 04:30:00
| null |
ON TRACK TO RESUME PRODUCTION AFTER CYBER ATTACK.DOES NOT EXPECT A MAJOR IMPACT ON ITS BUSINESS.MOST ORDERS ARE FORESEEN TO BE EXECUTED WITHIN Q3.ONLY SOME DELIVERIES MAY HAVE TO BE SHIFTED TO Q4 AFTER CLOSE ALIGNMENT WITH RESPECTIVE CUSTOMERS.ALL OTHER SITES WILL FOLLOW WITHIN A WEEK'S TIME FRAME FROM NOW.AFTER A DETAILED CHECK, X-FAB DOES NOT ANTICIPATE DAMAGE TO WORK IN PROGRESS CAUSED BY SUDDEN STOP OF ITS PRODUCTION LINES.FINANCIAL IMPACT OF CYBER ATTACK IS NOT EXPECTED TO BE MATERIAL.PUBLICATION OF THE SECOND QUARTER RESULTS INITIALLY PLANNED FOR JULY 30 WILL BE POSTPONED TO AUGUST 27, 2020.
|
X FAB SILICON FOUNDRIES TO RESUME PRODUCTION AFTER CYBER ATTACK
|
XFAB.PA
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2020-04-30 04:30:00
| null |
Q1 NET LOSS -6.7 MILLION USD.Q1 REVENUE 126.9 MILLION USD.Q2 2020 REVENUE IS EXPECTED IN RANGE OF USD 118-128 MILLION WITH AN EBITDA MARGIN IN RANGE OF 5-9%.
|
X FAB ANNOUNCES Q1 NET LOSS OF 6.7 MILLION DOLLARS
|
XFAB.PA
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2020-04-02 14:30:00
| null |
X-FAB ANNOUNCES FIRST QUARTER REVENUES AND WITHDRAWS ITS FULL-YEAR GUIDANCE IN LIGHT OF THE COVID-19 PANDEMIC.X-FAB CLOSED Q1 OF 2020 WITH REVENUES AMOUNTING TO USD 126.8 MILLION (PRELIMINARY), WITHIN GUIDANCE RANGE OF USD 125-132 MILLION.Q1 2020 NOT IMPACTED BY THE COVID-19 PANDEMIC.THROUGHOUT ENTIRE Q1, BOOKINGS TRENDED UPWARDS RECORDING A TOTAL OF USD 148.2 MILLION.WITHDRAWAL OF FULL-YEAR GUIDANCE.VISIBILITY ON HOW X-FAB'S BUSINESS WILL EVOLVE IN REMAINDER OF YEAR IS LOW.IT CAN THEREFORE NO LONGER BE ENSURED THAT X-FAB WILL MEET FY GUIDANCE PROVIDED IN FEB THIS YEAR WITH ANTICIPATED REVENUE GROWTH OF 10%.
|
X-FAB WITHDRAWS FY 2020 GUIDANCE DUE TO COVID-19
|
XFAB.PA
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2020-03-17 12:30:00
| null |
STATEMENT FROM THE X-FAB MANAGEMENT TEAM ON THE CORONA VIRUS SITUATION.WE CONTINUE TO SHIP PRODUCTS IN AND OUT OF ALL COUNTRIES WHERE WE OPERATE.WE HAVE A DIVERSIFIED MANUFACTURING PRESENCE WITH SIX SITES ON THREE CONTINENTS AND ALL OUR PRODUCTION SITES ARE OPERATIONAL.WE HAVE ADVISED EMPLOYEES AND CONTRACTORS TO WORK FROM HOME IF THEY CAN.ON CORONAVIRUS: WE HAVE INSTALLED COMPREHENSIVE REVIEWS TO MONITOR AND PROACTIVELY ADDRESS ANY CONCERNS AND TO RETAIN OUR FOCUS ON CUSTOMERS.CURRENTLY, WE HAVE NO ISSUES WITH SUPPLIERS THAT COULD IMPACT SHIPMENTS TO OUR CUSTOMERS.WE ARE ADHERING TO LOCAL GOVERNMENT REQUIREMENTS ON SELF-QUARANTINING WHEN REQUIRED .
|
X-FAB CONTINUES TO SHIP PRODUCTS DESPITE CORONAVIRUS
|
XFAB.PA
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2020-02-11 15:30:00
| null |
X-FAB FOURTH QUARTER AND FULL YEAR 2019 RESULTS.Q4 REVENUE WAS USD 113.4 MILLION.Q1 2020 REVENUE IS EXPECTED IN RANGE OF USD 125-132 MILLION WITH AN EBITDA MARGIN IN RANGE OF 6-10%.Q4 EBITDA WAS USD -2.6 MILLION, DOWN 116% YEAR-ON-YEAR AND DOWN 120% QUARTER-ON-QUARTER.Q4 NET LOSS WAS USD -22.4 MILLION, DOWN USD 17.9 MILLION YEAR-ON-YEAR AND DOWN USD 14.3 MILLION QUARTER-ON-QUARTER.Q1 2020 REVENUE IS EXPECTED IN RANGE OF USD 125-132 MILLION.X FAB SILICON FOUNDRIES EV SEES Q1 EBITDA MARGIN IN RANGE OF 6-10%.FOR FULL YEAR 2020, MANAGEMENT EXPECTS REVENUE TO GROW BY APPROXIMATELY 10%.X FAB SILICON FOUNDRIES EV SEES FY EBITDA MARGIN IN RANGE OF 10-15%.
|
X-FAB Q4 EBITDA TURNS TO LOSS OF USD 2.6 MILLION
|
XFAB.PA
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2019-10-29 15:30:00
| null |
Q3 NET LOSS IS USD 8.2 MLN, DOWN USD 20.3 MLN YEAR-ON-YEAR AND DOWN USD 0.1 MILLION QUARTER-ON-QUARTER.Q4 2019 REVENUE IS EXPECTED IN RANGE OF USD 111 MLN TO 118 MLN WITH EBITDA MARGIN IN RANGE OF 1 TO 7%.Q3 EBITDA IS USD 12.7 MLN, DOWN 57% YEAR-ON-YEAR AND UP 8% QUARTER-ON-QUARTER; EBITDA MARGIN OF 10%, ON UPPER END OF 4% TO 10% GUIDANCE.VISIBILITY ON Q4 REMAINS LIMITED.Q3 EBIT USD IS -6.1 MLN, DOWN USD 20.5 MILLION YEAR-ON-YEAR AND DOWN USD 0.5 MILLION QUARTER-ON-QUARTER.Q4 2019 GUIDANCE IS BASED ON AVERAGE EXCHANGE RATE OF USD/EUR 1.12.Q3 REVENUE IS USD 130.5 MLN, WITHIN GUIDANCE OF USD 128 TO 135 MLN, DOWN 14% YEAR-ON-YEAR AND 1% QUARTER-ON-QUARTER.
|
X-FAB Q3 NET LOSS IS 8.2 MILLION DOLLARS, DOWN YEAR-ON-YEAR
|
XFAB.PA
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2019-10-28 22:30:00
| null |
X-FAB SILICON FOUNDRIES SE PROVIDED EARNINGS GUIDANCE FOR FOURTH QUARTER OF 2019. FOR THE QUARTER, REVENUE IS EXPECTED IN THE RANGE OF USD 111 MILLION TO USD 118 MILLION.
|
X-FAB SILICON FOUNDRIES SE PROVIDES EARNINGS GUIDANCE FOR FOURTH QUARTER OF 2019
|
XFAB.PA
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-05-05 14:28:00
| null |
TICKETS FOR XFC GRAND PRIX™ ON SALE NOW AT XFCFIGHT.COM DETROIT , MAY 5, 2023 /PRNEWSWIRE/ -- FIGHTERS ARE GRAPPLING TO GET ON THE UNDERCARD AND THE TOP MATCHUPS ARE SET FOR XFC GRAND PRIX™, A PREMIER MMA PROFESSIONAL FIGHT NIGHT EVENT HAPPENING JUNE 2, 2023, AT THE WAYNE STATE FIELDHOUSE IN DOWNTOWN DETROIT. IN THE MAIN EVENT, MUHAMMED "MUSCLE" DEREESE TAKES ON BOBBY "THE FREAK" BRENTS IN A HEAVYWEIGHT BOUT FOR THE AGES.
|
XTREME FIGHTING CHAMPIONSHIPS (XFC) ANNOUNCES TOP MATCHUPS FOR MMA EVENT ON DETROIT GRAND PRIX WEEKEND
|
XFCI
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-04-26 18:26:00
| null |
NEW LEADERSHIP KICKS OFF POST-COVID FIGHT CALENDAR WITH XFC GRAND PRIX JUNE 2 NEW LEADERSHIP KICKS OFF POST-COVID FIGHT CALENDAR WITH XFC GRAND PRIX JUNE 2
|
TIM NORTHUP APPOINTED CHIEF FINANCIAL OFFICER AND JEFFREY LAMBERT APPOINTED AS INDEPENDENT DIRECTOR OF XTREME FIGHTING CHAMPIONSHIPS
|
XFCI
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-04-20 10:30:00
| null |
XFC GRAND PRIX™ WAVES GREEN FLAG ON THE OFFICIAL RETURN OF THE CHEVROLET DETROIT GRAND PRIX PRESENTED BY LEAR TO THE DOWNTOWN STREETS OF THE MOTOR CITY DETROIT , APRIL 20, 2023 /PRNEWSWIRE/ -- FIGHTERS, START YOUR ENGINES! XTREME FIGHTING CHAMPIONSHIPS ("XFC"), A PREMIER INTERNATIONAL MIXED MARTIAL ARTS ORGANIZATION (XFCI: OTC US), RETURNS TO ACTION WITH XFC GRAND PRIX™, A PREMIER MMA PROFESSIONAL FIGHT NIGHT EVENT SCHEDULED FOR JUNE 2, 2023, AT THE WAYNE STATE FIELDHOUSE IN DOWNTOWN DETROIT.
|
XTREME FIGHTING CHAMPIONSHIPS (XFC) ANNOUNCES TRIUMPHANT RETURN TO MMA ACTION WITH FIGHT EVENT ON DETROIT GRAND PRIX WEEKEND
|
XFCI
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-11-09 07:00:00
| null |
CLUB FIGHT 1 WILL BE XFC'S FIRST IN-PERSON FIGHT OF 2022, LAUNCHING IN ORLANDO, FLORIDA CLUB FIGHT 1 WILL BE XFC'S FIRST IN-PERSON FIGHT OF 2022, LAUNCHING IN ORLANDO, FLORIDA
|
XTREME FIGHTING CHAMPIONS ANNOUNCES CLUB FIGHT 1
|
XFCI
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-05-09 07:00:00
| null |
MIAMI, MAY 09, 2022 (GLOBE NEWSWIRE) -- XTREME FIGHTING CHAMPIONSHIPS (“XFC” OR “THE COMPANY”), THE SECOND LARGEST PUBLICLY TRADED PREMIER INTERNATIONAL MIXED MARTIAL ARTS (“MMA”) ORGANIZATION, RELEASED ITS FINANCIAL RESULTS FOR THE FISCAL YEAR ENDED DECEMBER 31, 2021.
|
XTREME FIGHTING CHAMPIONSHIPS ANNOUNCES FULL YEAR 2021 RESULTS WITH REVENUE INCREASING 487%
|
XFCI
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-06-26 09:54:00
| null |
RANKED FIRST AMONG MWA MEDICAL DEVICE PROVIDERS IN THYROID NODULE AND BREAST LUMP TREATMENT WITH APPROXIMATELY 35% MARKET SHARE IN CHINA [1] EXTENSIVE DISTRIBUTION NETWORK WITH OVER 430 HOSPITALS PENETRATED AND NATIONAL COVERAGE ACROSS 21 PROVINCES, MUNICIPALITIES, AND AUTONOMOUS REGIONS IN CHINA PROPOSED TRANSACTION REPRESENTS A PRE-MONEY EQUITY VALUE OF $300 MILLION FOR BAIRD MEDICAL AND AN IMPLIED PRO FORMA ENTERPRISE VALUE OF APPROXIMATELY $370 MILLION FOR THE COMBINED COMPANY EXISTING BETTERS SHAREHOLDERS WILL ROLL 100% OF THEIR CURRENT EQUITY HOLDINGS INTO EQUITY OF THE COMBINED COMPANY SAN FRANCISCO AND GUANGZHOU, CHINA , JUNE 26, 2023 /PRNEWSWIRE/ -- BAIRD MEDICAL INVESTMENT HOLDINGS LIMITED ("BAIRD MEDICAL" OR THE "COMPANY"),[2] A MEDICAL TECHNOLOGY COMPANY, AND EXCELFIN ACQUISITION CORP. ("EXCELFIN") (NASDAQ: XFIN), A PUBLICLY TRADED SPECIAL PURPOSE ACQUISITION COMPANY, HAVE ENTERED INTO A DEFINITIVE BUSINESS COMBINATION AGREEMENT THAT WOULD RESULT IN BAIRD MEDICAL BECOMING A PUBLICLY TRADED COMPANY. UPON THE CLOSING OF THE PROPOSED TRANSACTION BETWEEN BETTERS AND EXCELFIN, THE COMBINED COMPANY WILL OPERATE AS BAIRD MEDICAL INVESTMENT HOLDINGS LIMITED AND BE LISTED ON THE NASDAQ UNDER THE NEW TICKER SYMBOL BDMD.
|
BAIRD MEDICAL, A LEADING DEVELOPER AND PROVIDER OF MICROWAVE ABLATION (MWA) MEDICAL DEVICES IN CHINA, TO BE PUBLICLY LISTED ON NASDAQ THROUGH A PROPOSED BUSINESS COMBINATION WITH EXCELFIN ACQUISITION CORP.
|
XFIN
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-07-03 13:15:00
| null |
CHICAGO--(BUSINESS WIRE)--XAI OCTAGON FLOATING RATE & ALTERNATIVE INCOME TERM TRUST (THE “TRUST”) HAS DECLARED ITS REGULAR MONTHLY DISTRIBUTION OF $0.085 PER SHARE OF THE TRUST'S COMMON SHARES (NYSE: XFLT). THE TRUST ALSO DECLARED PREFERRED DIVIDENDS FOR THE QUARTER OF $0.40625 PER SHARE OF THE TRUST'S 6.50% SERIES 2026 TERM PREFERRED SHARES (NYSE: XFLTPRA). THE FOLLOWING DATES APPLY TO EACH DECLARATION: SHARE CLASS EX-DIVIDEND DATE RECORD DATE PAYABLE DATE AMOUNT CHANGE FROM PREVIOUS DECLA.
|
XAI OCTAGON FLOATING RATE & ALTERNATIVE INCOME TERM TRUST DECLARES ITS MONTHLY COMMON SHARES DISTRIBUTION AND QUARTERLY PREFERRED SHARES DIVIDEND
|
XFLT
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-05-09 16:15:00
| null |
CHICAGO--(BUSINESS WIRE)--XAI OCTAGON FLOATING RATE & ALTERNATIVE INCOME TERM TRUST (NYSE: XFLT) (THE “TRUST”) TODAY ANNOUNCED THAT IT PLANS TO HOST THE TRUST'S QUARTERLY WEBINAR ON MAY 25, 2023 AT 12:00 PM (EASTERN TIME). KIMBERLY FLYNN, MANAGING DIRECTOR AT XA INVESTMENTS (“XAI”) WILL MODERATE THE Q&A STYLE WEBINAR WITH STEVEN PERRY, VICE PRESIDENT AT XAI, AND GRETCHEN LAM, SENIOR PORTFOLIO MANAGER AT OCTAGON CREDIT INVESTORS. TO JOIN VIA WEB: PLEASE GO TO THE KNOWLEDGE BANK SECTION O.
|
XAI OCTAGON FLOATING RATE & ALTERNATIVE INCOME TERM TRUST WILL HOST Q1 2023 QUARTERLY WEBINAR ON MAY 25, 2023
|
XFLT
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-05-01 16:15:00
| null |
CHICAGO--(BUSINESS WIRE)--XAI OCTAGON FLOATING RATE & ALTERNATIVE INCOME TERM TRUST (THE “TRUST”) HAS DECLARED ITS REGULAR MONTHLY DISTRIBUTION OF $0.085 PER SHARE ON THE TRUST'S COMMON SHARES (NYSE: XFLT), PAYABLE ON JUNE 1, 2023, TO COMMON SHAREHOLDERS OF RECORD AS OF MAY 16, 2023, AS NOTED BELOW. THE AMOUNT OF THE DISTRIBUTION REPRESENTS A 16.44% INCREASE FROM THE PREVIOUS MONTH'S DISTRIBUTION AMOUNT OF $0.073 PER SHARE. THE FOLLOWING DATES APPLY TO THE DECLARATION: EX-DIVIDEND DATE.
|
XAI OCTAGON FLOATING RATE & ALTERNATIVE INCOME TERM TRUST DECLARES ITS MONTHLY COMMON SHARES DISTRIBUTION OF $0.085 PER SHARE
|
XFLT
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-02-21 10:13:00
| null |
CHICAGO--(BUSINESS WIRE)--XAI OCTAGON FLOATING RATE & ALTERNATIVE INCOME TERM TRUST (NYSE: XFLT) (THE “TRUST”) TODAY ANNOUNCED THAT IT PLANS TO HOST THE TRUST'S QUARTERLY WEBINAR ON MARCH 2, 2023 AT 11:00 AM (EASTERN TIME). ROBERT CHENOWETH, VICE PRESIDENT AT XA INVESTMENTS (“XAI”) WILL MODERATE THE Q&A STYLE WEBINAR WITH KIMBERLY FLYNN, MANAGING DIRECTOR AT XAI, AND GRETCHEN LAM, SENIOR PORTFOLIO MANAGER AT OCTAGON CREDIT INVESTORS.
|
XAI OCTAGON FLOATING RATE & ALTERNATIVE INCOME TERM TRUST WILL HOST Q4 2022 QUARTERLY WEBINAR ON MARCH 2, 2023
|
XFLT
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-02-01 16:15:00
| null |
CHICAGO--( BUSINESS WIRE )--XAI OCTAGON FLOATING RATE & ALTERNATIVE INCOME TERM TRUST (THE “TRUST”) HAS DECLARED ITS REGULAR MONTHLY DISTRIBUTION OF $0.073 PER SHARE ON THE TRUST'S COMMON SHARES (NYSE: XFLT), PAYABLE ON MARCH 1, 2023 TO COMMON SHAREHOLDERS OF RECORD AS OF FEBRUARY 15, 2023, AS NOTED BELOW. THE AMOUNT OF THE DISTRIBUTION REPRESENTS NO CHANGE FROM THE PREVIOUS MONTH'S DISTRIBUTION AMOUNT.
|
XAI OCTAGON FLOATING RATE & ALTERNATIVE INCOME TERM TRUST DECLARES ITS MONTHLY COMMON SHARES DISTRIBUTION OF $0.073 PER SHARE
|
XFLT
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-01-03 16:15:00
| null |
CHICAGO--( BUSINESS WIRE )--XAI OCTAGON FLOATING RATE & ALTERNATIVE INCOME TERM TRUST (THE “TRUST”) HAS DECLARED ITS REGULAR MONTHLY DISTRIBUTION OF $0.073 PER SHARE OF THE TRUST'S COMMON SHARES (NYSE: XFLT). THE TRUST ALSO DECLARED PREFERRED DIVIDENDS FOR THE QUARTER OF $0.40625 PER SHARE OF THE TRUST'S 6.50% SERIES 2026 TERM PREFERRED SHARES (NYSE: XFLTPRA).
|
XAI OCTAGON FLOATING RATE & ALTERNATIVE INCOME TERM TRUST DECLARES ITS MONTHLY COMMON SHARES DISTRIBUTION AND QUARTERLY PREFERRED SHARES DIVIDEND
|
XFLT
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-11-28 15:53:00
| null |
CHICAGO--( BUSINESS WIRE )--XAI OCTAGON FLOATING RATE & ALTERNATIVE INCOME TERM TRUST (NYSE: XFLT) (THE “TRUST”) TODAY ANNOUNCED THAT IT PLANS TO HOST THE TRUST'S QUARTERLY WEBINAR ON DECEMBER 1, 2022 AT 11:00 AM (EASTERN TIME). ROBERT CHENOWETH, VICE PRESIDENT AT XA INVESTMENTS (“XAI”) WILL MODERATE THE Q&A STYLE WEBINAR WITH KIMBERLY FLYNN, MANAGING DIRECTOR AT XAI, AND GRETCHEN LAM, SENIOR PORTFOLIO MANAGER AT OCTAGON CREDIT INVESTORS.
|
XAI OCTAGON FLOATING RATE & ALTERNATIVE INCOME TERM TRUST WILL HOST Q3 2022 QUARTERLY WEBINAR ON DECEMBER 1, 2022
|
XFLT
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-10-03 16:15:00
| null |
CHICAGO--(BUSINESS WIRE)--XAI OCTAGON FLOATING RATE & ALTERNATIVE INCOME TERM TRUST (THE “TRUST”) HAS DECLARED ITS REGULAR MONTHLY DISTRIBUTION OF $0.073 PER SHARE OF THE TRUST'S COMMON SHARES (NYSE: XFLT). THE TRUST ALSO DECLARED PREFERRED DIVIDENDS FOR THE QUARTER OF $0.40625 PER SHARE OF THE TRUST'S 6.50% SERIES 2026 TERM PREFERRED SHARES (NYSE: XFLTPRA). THE FOLLOWING DATES APPLY TO EACH DECLARATION: SHARE CLASS EX-DIVIDEND DATE RECORD DATE PAYABLE DATE AMOUNT CHANGE FROM PREV
|
XAI OCTAGON FLOATING RATE & ALTERNATIVE INCOME TERM TRUST DECLARES ITS MONTHLY COMMON SHARES DISTRIBUTION AND QUARTERLY PREFERRED SHARES DIVIDEND
|
XFLT
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-09-27 11:15:00
| null |
CHICAGO--(BUSINESS WIRE)--XA INVESTMENTS (“XAI”), A CHICAGO-BASED ALTERNATIVE ASSET MANAGER, CELEBRATES THE 5TH ANNIVERSARY OF THE XAI OCTAGON FLOATING RATE & ALTERNATIVE INCOME TERM TRUST (NYSE: XFLT) (“XFLT” OR THE “TRUST”). OCTAGON CREDIT INVESTORS, LLC (“OCTAGON”) SERVES AS THE TRUST'S INVESTMENT SUB-ADVISER. THE TRUST WAS LAUNCHED ON SEPTEMBER 27, 2017 WITH $82 MILLION IN NET ASSETS AND HAS MADE SEVERAL ACCRETIVE FOLLOW-ON EQUITY OFFERINGS IN ADDITION TO THE ISSUANCE OF SHARES PURSUANT
|
XAI OCTAGON FLOATING RATE & ALTERNATIVE INCOME TERM TRUST CELEBRATES 5TH ANNIVERSARY
|
XFLT
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-08-09 17:30:00
| null |
CHICAGO--(BUSINESS WIRE)--XAI OCTAGON FLOATING RATE & ALTERNATIVE INCOME TERM TRUST (NYSE: XFLT) (THE “TRUST”) TODAY ANNOUNCED THAT IT PLANS TO HOST THE TRUST'S QUARTERLY WEBINAR ON AUGUST 18, 2022 AT 11:00 AM (EASTERN TIME). ROBERT CHENOWETH, VICE PRESIDENT AT XA INVESTMENTS (“XAI”) WILL MODERATE THE Q&A STYLE WEBINAR WITH KIMBERLY FLYNN, MANAGING DIRECTOR AT XAI, AND GRETCHEN LAM, SENIOR PORTFOLIO MANAGER AT OCTAGON CREDIT INVESTORS. TO JOIN VIA WEB: PLEASE GO TO THE KNOWLEDGE BANK SE
|
XAI OCTAGON FLOATING RATE & ALTERNATIVE INCOME TERM TRUST WILL HOST Q2 2022 QUARTERLY WEBINAR ON AUGUST 18, 2022
|
XFLT
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-07-01 16:15:00
| null |
CHICAGO--(BUSINESS WIRE)--XAI OCTAGON FLOATING RATE & ALTERNATIVE INCOME TERM TRUST (THE “TRUST”) HAS DECLARED ITS REGULAR MONTHLY DISTRIBUTION OF $0.073 PER SHARE OF THE TRUST'S COMMON SHARES (NYSE: XFLT). THE TRUST ALSO DECLARED PREFERRED DIVIDENDS FOR THE QUARTER OF $0.40625 PER SHARE OF THE TRUST'S 6.50% SERIES 2026 TERM PREFERRED SHARES (NYSE: XFLTPRA). THE FOLLOWING DATES APPLY TO EACH DECLARATION: SHARE CLASS EX-DIVIDEND DATE RECORD DATE PAYABLE DATE AMOUNT CHANGE FROM PREVIOUS DECLA
|
XAI OCTAGON FLOATING RATE & ALTERNATIVE INCOME TERM TRUST DECLARES ITS MONTHLY COMMON SHARES DISTRIBUTION AND QUARTERLY PREFERRED SHARES DIVIDEND
|
XFLT
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-06-30 20:51:00
| null |
CHICAGO--(BUSINESS WIRE)--XAI OCTAGON FLOATING RATE & ALTERNATIVE INCOME TERM TRUST (THE “TRUST”) (NYSE: XFLT), A DIVERSIFIED, CLOSED-END MANAGEMENT INVESTMENT COMPANY WITH AN INVESTMENT OBJECTIVE TO SEEK ATTRACTIVE TOTAL RETURN WITH AN EMPHASIS ON INCOME GENERATION ACROSS MULTIPLE STAGES OF THE CREDIT CYCLE, HAS CLOSED ITS PREVIOUSLY ANNOUNCED PRIVATE PLACEMENT OF 400,000 SHARES OF THE TRUST'S 6.00% SERIES 2029 CONVERTIBLE PREFERRED SHARES DUE JUNE 2029, LIQUIDATION PREFERENCE $25.00 PER S
|
XAI OCTAGON FLOATING RATE & ALTERNATIVE INCOME TERM TRUST CLOSES PRIVATE PLACEMENT OF CONVERTIBLE PREFERRED SHARES AND REGISTERED DIRECT PLACEMENT OF COMMON SHARES
|
XFLT
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-06-28 19:38:00
| null |
CHICAGO--(BUSINESS WIRE)--XAI OCTAGON FLOATING RATE & ALTERNATIVE INCOME TERM TRUST (THE “TRUST”) (NYSE: XFLT), A DIVERSIFIED, CLOSED-END MANAGEMENT INVESTMENT COMPANY WITH AN INVESTMENT OBJECTIVE TO SEEK ATTRACTIVE TOTAL RETURN WITH AN EMPHASIS ON INCOME GENERATION ACROSS MULTIPLE STAGES OF THE CREDIT CYCLE, HAS ENTERED INTO A PURCHASE AGREEMENT WITH CERTAIN INSTITUTIONAL INVESTORS FOR THE PURCHASE AND SALE OF 400,000 SHARES OF THE TRUST'S 6.00% SERIES 2029 CONVERTIBLE PREFERRED SHARES DUE
|
XAI OCTAGON FLOATING RATE & ALTERNATIVE INCOME TERM TRUST ANNOUNCES PRIVATE PLACEMENT OF CONVERTIBLE PREFERRED SHARES AND REGISTERED DIRECT PLACEMENT OF COMMON SHARES
|
XFLT
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-05-02 16:15:00
| null |
CHICAGO--(BUSINESS WIRE)--XAI OCTAGON FLOATING RATE & ALTERNATIVE INCOME TERM TRUST (THE “TRUST”) HAS DECLARED ITS REGULAR MONTHLY DISTRIBUTION OF $0.073 PER SHARE ON THE TRUST'S COMMON SHARES (NYSE: XFLT), PAYABLE ON JUNE 1, 2022 TO COMMON SHAREHOLDERS OF RECORD AS OF MAY 16, 2022, AS NOTED BELOW. THE AMOUNT OF THE DISTRIBUTION REPRESENTS NO CHANGE FROM THE PREVIOUS MONTH'S DISTRIBUTION AMOUNT. THE FOLLOWING DATES APPLY TO THE DECLARATION: EX-DIVIDEND DATE MAY 13, 2022 RECORD DATE
|
XAI OCTAGON FLOATING RATE & ALTERNATIVE INCOME TERM TRUST DECLARES ITS MONTHLY COMMON SHARES DISTRIBUTION OF $0.073 PER SHARE
|
XFLT
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-04-01 16:15:00
| null |
CHICAGO--(BUSINESS WIRE)--XAI OCTAGON FLOATING RATE & ALTERNATIVE INCOME TERM TRUST (THE “TRUST”) HAS DECLARED ITS REGULAR MONTHLY DISTRIBUTION OF $0.073 PER SHARE OF THE TRUST'S COMMON SHARES (NYSE: XFLT). THE TRUST ALSO DECLARED PREFERRED DIVIDENDS FOR THE QUARTER OF $0.40625 PER SHARE OF THE TRUST'S 6.50% SERIES 2026 TERM PREFERRED SHARES (NYSE: XFLTPRA). THE FOLLOWING DATES APPLY TO EACH DECLARATION: SHARE CLASS EX-DIVIDEND DATE RECORD DATE PAYABLE DATE AMOUNT CHANGE FROM PREVIOUS DECLA
|
XAI OCTAGON FLOATING RATE & ALTERNATIVE INCOME TERM TRUST DECLARES ITS MONTHLY COMMON SHARES DISTRIBUTION AND QUARTERLY PREFERRED SHARES DIVIDEND
|
XFLT
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-03-01 16:15:00
| null |
CHICAGO--(BUSINESS WIRE)--XAI OCTAGON FLOATING RATE & ALTERNATIVE INCOME TERM TRUST (THE “TRUST”) HAS DECLARED ITS REGULAR MONTHLY DISTRIBUTION OF $0.073 PER SHARE ON THE TRUST'S COMMON SHARES (NYSE: XFLT), PAYABLE ON APRIL 1, 2022 TO COMMON SHAREHOLDERS OF RECORD AS OF MARCH 15, 2022, AS NOTED BELOW. THE AMOUNT OF THE DISTRIBUTION REPRESENTS NO CHANGE FROM THE PREVIOUS MONTH'S DISTRIBUTION AMOUNT. THE FOLLOWING DATES APPLY TO THE DECLARATION: EX-DIVIDEND DATE MARCH 14, 2022 RECORD DATE
|
XAI OCTAGON FLOATING RATE & ALTERNATIVE INCOME TERM TRUST DECLARES ITS MONTHLY COMMON SHARES DISTRIBUTION OF $0.073 PER SHARE
|
XFLT
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-02-01 16:15:00
| null |
CHICAGO--(BUSINESS WIRE)--XAI OCTAGON FLOATING RATE & ALTERNATIVE INCOME TERM TRUST (THE “TRUST”) HAS DECLARED ITS REGULAR MONTHLY DISTRIBUTION OF $0.073 PER SHARE ON THE TRUST'S COMMON SHARES (NYSE: XFLT), PAYABLE ON MARCH 1, 2022 TO COMMON SHAREHOLDERS OF RECORD AS OF FEBRUARY 15, 2022, AS NOTED BELOW. THE AMOUNT OF THE DISTRIBUTION REPRESENTS NO CHANGE FROM THE PREVIOUS MONTH'S DISTRIBUTION AMOUNT. THE FOLLOWING DATES APPLY TO THE DECLARATION: EX-DIVIDEND DATE FEBRUARY 14, 2022 RECORD
|
XAI OCTAGON FLOATING RATE & ALTERNATIVE INCOME TERM TRUST DECLARES ITS MONTHLY COMMON SHARES DISTRIBUTION OF $0.073 PER SHARE
|
XFLT
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.